GYRE Valuation

Gyre Therapeutics Inc

Add to Watchlist

Advanced Chart

7.360

-0.39(-5.032%)1D

GYRE Relative Valuation

GYRE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GYRE is overvalued; if below, it's undervalued.

Historical Valuation

Gyre Therapeutics Inc (GYRE) is now in the Fair zone, suggesting that its current forward PS ratio of 7.75 is considered Fairly compared with the five-year average of 9.16. The fair price of Gyre Therapeutics Inc (GYRE) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：7.41

Fair

24.74

Trailing

Forward

49.70

EV/EBITDA

Gyre Therapeutics Inc. (GYRE) has a current EV/EBITDA of 49.70. The 5-year average EV/EBITDA is 5.74. The thresholds are as follows: Strongly Undervalued below -25.81, Undervalued between -25.81 and -10.03, Fairly Valued between 21.51 and -10.03, Overvalued between 21.51 and 37.29, and Strongly Overvalued above 37.29. The current Forward EV/EBITDA of 49.70 falls within the Strongly Overvalued range.

144.16

EV/EBIT

Gyre Therapeutics Inc. (GYRE) has a current EV/EBIT of 144.16. The 5-year average EV/EBIT is 7.42. The thresholds are as follows: Strongly Undervalued below -26.84, Undervalued between -26.84 and -9.71, Fairly Valued between 24.56 and -9.71, Overvalued between 24.56 and 41.69, and Strongly Overvalued above 41.69. The current Forward EV/EBIT of 144.16 falls within the Strongly Overvalued range.

7.75

Gyre Therapeutics Inc. (GYRE) has a current PS of 7.75. The 5-year average PS is 1.06. The thresholds are as follows: Strongly Undervalued below -3.40, Undervalued between -3.40 and -1.17, Fairly Valued between 3.29 and -1.17, Overvalued between 3.29 and 5.52, and Strongly Overvalued above 5.52. The current Forward PS of 7.75 falls within the Strongly Overvalued range.

53.94

P/OCF

Gyre Therapeutics Inc. (GYRE) has a current P/OCF of 53.94. The 5-year average P/OCF is 4.79. The thresholds are as follows: Strongly Undervalued below -11.68, Undervalued between -11.68 and -3.45, Fairly Valued between 13.03 and -3.45, Overvalued between 13.03 and 21.26, and Strongly Overvalued above 21.26. The current Forward P/OCF of 53.94 falls within the Strongly Overvalued range.

63.99

P/FCF

Gyre Therapeutics Inc. (GYRE) has a current P/FCF of 63.99. The 5-year average P/FCF is 0.13. The thresholds are as follows: Strongly Undervalued below -5.66, Undervalued between -5.66 and -2.76, Fairly Valued between 3.02 and -2.76, Overvalued between 3.02 and 5.92, and Strongly Overvalued above 5.92. The current Forward P/FCF of 63.99 falls within the Strongly Overvalued range.

Gyre Therapeutics Inc (GYRE) has a current Price-to-Book (P/B) ratio of 7.65. Compared to its 3-year average P/B ratio of -6.40 , the current P/B ratio is approximately -219.48% higher. Relative to its 5-year average P/B ratio of -6.40, the current P/B ratio is about -219.48% higher. Gyre Therapeutics Inc (GYRE) has a Forward Free Cash Flow (FCF) yield of approximately -0.01%. Compared to its 3-year average FCF yield of -0.02%, the current FCF yield is approximately -38.65% lower. Relative to its 5-year average FCF yield of -0.02% , the current FCF yield is about -38.65% lower.

7.65

P/B

Median3y

-6.40

Median5y

-6.40

-0.01

FCF Yield

Median3y

-0.02

Median5y

-0.02

Competitors Valuation Multiple

The average P/S ratio for GYRE's competitors is 7.81, providing a benchmark for relative valuation. Gyre Therapeutics Inc Corp (GYRE) exhibits a P/S ratio of 7.75, which is -0.73% above the industry average. Given its robust revenue growth of 6.13%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

GYRE.O

Gyre Therapeutics Inc

MapLight Therapeutics Inc

16.92

737.98M

ATXS.O

Astria Therapeutics Inc

Esperion Therapeutics Inc

Performance Decomposition

Market capitalization of GYRE decreased by 41.17% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 380.54 to 456.50.

The secondary factor is the Revenue Growth, contributed 6.13%to the performance.

Overall, the performance of GYRE in the past 1 year is driven by P/E Change. Which is more unsustainable.

6.13%

25.23M → 26.77M

Revenue Growth

-67.26%

17.99 → 5.89

Margin Expansion

19.96%

380.54 → 456.50

P/E Change

-41.17%